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Geriatricians are pioneers in the field of care to a new
generation of patients, namely the very old. As stressed by
Dr. Goodwin (1), this population class is really heteroge-
neous, but its main characteristic is the ability to survive,
while the frail elderly die earlier. This natural process selects
the more robust. Furthermore, the inclusion criteria in most
of the randomized studies are so numerous that the selected
participants constitute without doubt a particular and even
more vigorous sample of the very old. Considering this
reality, the author’s provocative geriatrician point of view is
really challenging, because the latter discusses ‘‘evidence-
based medicine’’ data to better manage the growing number
of older hypertensive and comorbid patients the geriatrician
cares for in his daily practice.
Goodwin’s current courageous counter-approach raises
many interesting questions concerning, in particular,
changes of the cardiovascular risk profile of the very old
population. In the 80 years and older population, cardio-
vascular risk is poorly related to hypercholesterolemia or
elevated mean blood pressure, but positively associated with
pulse pressure and increased arterial stiffness (2,3). Further-
more, among other bad predictors, neck murmurs were men-
tioned in women, historical heart failure, proteinuria, and
tachycardia in men, and historical stroke and myocardial
infarction, pulmonary disease, left ventricular hypertrophy,
diabetes, and uricemia in both genders (3).
Considering these age-related risk factor changes and
comorbidity roles in the very old, it is interesting to stress
that, in Goodwin’s sources of information, no mention was
made of:
 Pulse pressure values, which appear to be extremely
valuable epidemiological data to evaluate the impact of
blood pressure treatment (4), or
 Multiple cardiovascular and noncardiovascular history
and comorbidity of the treated and nontreated hyperten-
sive very old population.
Moreover, side effects of antihypertensive treatments are
dependent of both:
 The choice of antihypertensive drug or drug association,
its pharmacological actions (volume depletion, hormone
blockage, or vascular impact), dosage, and tolerance.
 The patient himself/herself with his/her comorbidity
(particularly psychogeriatric disturbances and his/her
drug sensibility, but also of his/her drug compliance
and the quality of patient follow-up by the doctor).
Taken together, these difficulties indicate that only new
paradigms, as proposed by Goodwin (1), and new pro-
spective studies should be developed to respond to the 2
questions:
1. What is the ‘‘blood pressure’’ threshold to treat or not to
treat?
2. What are the most powerful drugs capable to reduce
cardiovascular morbidity and mortality?
To our knowledge, for such studies, any new approach
should take into account the following points:
 The real clinical difficulty to determine blood pressure in
elderly people. Incidentally, we understand that blood
pressure was only measured once in the follow-up
survival study by Boshuizen and colleagues (5). Is there
any better way of including, treating, and managing the
follow-up of arterial hypertension, notably in the very
old?
 When arterial stiffness is taken into account in epidemi-
ological studies, the role of blood pressure itself, as
a cardiovascular risk factor, disappears, while the inde-
pendent predictive role of arterial stiffness and wave
reflections appear clearly in these old patients (2).
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 Finally, whereas many drugs are able to decrease mean
blood pressure, basic research never developed (with
some exceptions) drugs able to reduce independently
large artery stiffness (6,7).
Here is the new paradigm derived from Dr. Goodwin’s
analysis.
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